No Data
No Data
Adverum Biotechnologies Analyst Ratings
RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Adverum Biotechnologies Price Target Lowered to $10 From $12 at RBC Capital
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment
No Data
No Data
QMengColdJoke : I am buying back, this designation itself means nothing but in the end will make final approval easier and faster.